Since BRAF-mutant cancer cells are highly dependent on MEK/ERK signaling, the combination of a BRAF inhibitor and a MEK inhibitor (double therapy) has shown a slight increased activity in comparison with either agent alone. The gene discussed is BRAF; the disease is cancer.